Technology
Health
Biotechnology

Translate Bio

$9.74
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.01 (0.09%) As of 2:24 PM EDT today
+$0.01 (0.09%) Today

Why Robinhood?

You can buy or sell Translate Bio and other stocks, options, ETFs, and crypto commission-free!

About TBIO

Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Read More Its lead product candidates include MRT5005 for the treatment of cystic fibrosis; and for the treatment of ornithine transcarbamylase deficiency. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA.

Employees
81
Headquarters
Lexington, Massachusetts
Founded
2011
Market Cap
440.71M
Price-Earnings Ratio
Dividend Yield
Average Volume
151.26K
High Today
$9.84
Low Today
$9.50
Open Price
$9.74
Volume
31.64K
52 Week High
$16.60
52 Week Low
$4.81

Collections

Technology
Health
Biotechnology
Research And Development
2018 IPO
US
North America

TBIO News

BenzingaJun 26

FDA Lifts Clinical Hold On Translate Bio's Liver Disorder Trial

309

TBIO Earnings

Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, After Hours

More TBIO News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.